# A Post-marketing Surveillance to Assess Safety and Efficacy of Rosuvatatin/Ezetimibe

> **NCT03648788** · — · UNKNOWN · sponsor: **IlDong Pharmaceutical Co Ltd** · enrollment: 600 (estimated)

## Conditions studied

- Mixed Dyslipidemia

## Interventions

- **OTHER:** NA (Observation study)

## Key facts

- **NCT ID:** NCT03648788
- **Lead sponsor:** IlDong Pharmaceutical Co Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-09
- **Primary completion:** 2024-06
- **Final completion:** 2024-08
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2018-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03648788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03648788, "A Post-marketing Surveillance to Assess Safety and Efficacy of Rosuvatatin/Ezetimibe". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03648788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*